Why the study?
Adverse pregnancy outcomes are associated with long-term maternal cardiovascular risk, making it important to understand risk modification strategies before, during, and after pregnancy to reduce adverse outcomes.
This review highlights the importance of cardiovascular risk assessment and modification in women with a history of adverse pregnancy outcomes to prevent future cardiovascular disease.
Supports considering enhanced postpartum CV surveillance; leaves open whether risk modification after adverse pregnancy outcomes reduces events.
Adverse pregnancy outcomes including hypertensive disorders of pregnancy and gestational diabetes are significant causes of maternal mortality. There is substantial evidence of an association between adverse events during pregnancy and long-term maternal cardiovascular risk. It is therefore important to understand the role of risk modification prior to, during, and after pregnancy to reduce adverse outcomes. These efforts include risk assessment, routine screening for cardiovascular risk factors, and potential pharmacotherapeutic risk reduction. In this manuscript, we aim to highlight the current evidence in the areas of cardiovascular risk assessment and risk modification, and the role for potential risk reduction therapies before, during, and after pregnancy.
No takes yet. Share an insight, caveat, or question.
Park et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: